Bibliography
- Giembycz MA, Lindsay MA. Pharmacology of the eosinophil. Pharmacol Rev 1999;51:213-340
- Williams TJ. The eosinophil enigma. J Clin Invest 2004;113:507-9
- Wenzel S. Physiologic and pathologic abnormalities in severe asthma. Clin Chest Med 2006;27:29-40. v
- Green RH, Brightling CE, McKenna S, Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:1715-21
- Pelaia G, Gallelli L, Romeo P, Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma. Int J Clin Pharmacol Ther 2011;49:713-21
- van Rensen EL, Evertse CE, van Schadewijk WA, Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009;64:72-80
- Hoshino M, Ohtawa J. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma. Respiration 2012 Jan 11. DOI: 10.1159/000334701 [Epub ahead of print]
- Molfino NA, Gossage D, Kolbeck R, Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2011 Sep 23. DOI: 10.1111/j.1365-2222.2011.03854.x [Epub ahead of print]
- Haldar P, Brightling CE, Hargadon B, Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84
- Nair P, Pizzichini MM, Kjarsgaard M, Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93
- Castro M, Mathur S, Hargreave F, Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-32
- Flood-Page P, Swenson C, Faiferman I, A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-71
- Corren J, Lemanske RF, Hanania NA, Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98
- Kolbeck R, Kozhich A, Koike M, MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010;125:1344-1353.e2
- Yan N, Shi Y. Mechanisms of apoptosis through structural biology. Annu Rev Cell Dev Biol 2005;21:35-56
- Busse WW, Katial R, Gossage D, Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010;125:1237-1244.e2
- Liu LY, Sedgwick JB, Bates ME, Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process. J Immunol 2002;169:6459-66
- Ghazi A, Trikha A, Calhoun WJ. Benralizumab - a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - a novel approach for the treatment of asthma. Expert Opin Biol Ther 2012;12:113-18
- Pavord ID, Jeffery PK, Qiu Y, Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. J Allergy Clin Immunol 2009;123:1083-9. e1-7